Who makes Half-Dose of novel OAC?

Half-Dose of novel OAC is developed by Texas Cardiac Arrhythmia Research Foundation.

What development phase is Half-Dose of novel OAC in?

Half-Dose of novel OAC is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Half-Dose of novel OAC

Texas Cardiac Arrhythmia Research Foundation · FDA-approved active Small molecule Quality 2/100

Half-Dose of novel OAC, marketed by Texas Cardiac Arrhythmia Research Foundation, holds a niche position in the oral anticoagulant market. The drug's key strength lies in its unique half-dose formulation, which may offer improved safety and efficacy profiles compared to standard doses. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Half-Dose of novel OAC
Sponsor	Texas Cardiac Arrhythmia Research Foundation
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results